Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial

Documents similaires

• An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
  par: Angela X. Chen, et autres
  Publié: (2024)
• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
  par: Navdeep Tangri, et autres
  Publié: (2024)
• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
  par: Kathryn Cardoza, et autres
  Publié: (2024)
• Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data
  par: Daniel Bekele Ketema, et autres
  Publié: (2025)
• Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
  par: Jiaqiang Zhang, et autres
  Publié: (2025)